Navigation Links
US HIFU Names New Chief Executive Officer
Date:1/6/2012

CHARLOTTE, N.C., Jan. 6, 2012 /PRNewswire/ -- USHIFU, LLC (US HIFU), a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies, appointed Michael Klein as the company's new chief executive officer and member of the board of directors. Mr. Klein brings more than 30 years of experience in oncology and the medical device industry to US HIFU, most recently as president of the radiation oncology division of Roper Industries, Inc., a publicly traded, diversified manufacturer of engineered products. US HIFU is backed by an investor syndicate led by Galen Partners, a leading healthcare growth equity and late stage venture capital firm.

(Logo: http://photos.prnewswire.com/prnh/20101109/CL98048LOGO )

US HIFU manufactures and distributes the Sonablate® 500 (Sonablate) medical device, designed to treat prostate cancer with HIFU energy. The prostate cancer procedure, known as Sonablate HIFU, is approved in more than 30 countries outside the United States and is currently under investigation in the US within an FDA approved IDE. Mr. Klein was selected for the role based, in part, on his significant experience overseeing clinical trials and interacting with the FDA. Specifically, Mr. Klein oversaw the clinical trial and PMA process for R2's computer-aided detection technology that received approval for both breast and lung cancer detection. During his tenure as CEO, the technology was cleared for US commercialization, achieved CPT-1 code approval and ramped to $55 million in annual revenue. This experience will be invaluable as Mr. Klein leads US HIFU through the final stages of the clinical trial in preparation for data submission to the FDA. In addition, he will oversee the company's other operations, including market development for the Sonablate outside of the United States and the Sonatherm™ 600, US HIFU's first 510(k)-cleared medical device.

Mr. Klein commented, "The promise of HIFU, as a precise, yet non-invasive treatment for prostate disease, is a technology that has clearly come of age. Emerging methods of care ranging from active surveillance to focal therapy serve as compliments to existing prostate treatments and provide new treatment options for clinicians and offer a broader range of treatment choices for patients. I couldn't be more excited to be joining US HIFU at this mission critical point in the development and adoption of this important technology."

Mr. Klein has a strong background in oncology in addition to his medical device experience. He served as president and CEO of Xoft, Inc., a position he held from 2005 until the sale of Xoft to iCAD, Inc. in December 2010. Mr. Klein led the development, approval and commercialization of Xoft's non-radioactive x-ray technology for radiation therapy for various cancers. He continues to serve on iCAD's board of directors. In 2008, while with Xoft, Mr. Klein received R&D Magazine's "Top 100 Award" which honors the 100 most technologically significant new products each year.

From 2000 to 2004, Mr. Klein served as chairman, president and CEO of R2 Technology, a company that produced computer-aided breast and lung cancer detection devices. R2 Technology was acquired by Hologic, Inc. He served as general manager of Varian Medical Systems' oncology group from 1997 to 2000, where he managed businesses ranging from $25 million to $250 million. Mr. Klein served on the board of directors of Sanarus Medical, a breast biopsy and cryoablation company focused on the treatment of fibroadenomas.

US HIFU makes the Sonablate HIFU treatment available to patients with prostate cancer in locations where it is approved or authorized and commercially available, such as Canada, Mexico, Bermuda and the Bahamas. London-based UKHIFU, Ltd (UK HIFU), another of the company's subsidiaries, distributes the Sonablate in Europe and Russia.

About USHIFU, LLC

USHIFU, LLC (US HIFU), a privately held healthcare company, is a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies. US HIFU is committed to treating prostate cancer using HIFU with the Sonablate® 500, a minimally invasive, outpatient procedure pioneered to control cancer and significantly improve patients' quality of life. The company is engaged in ongoing research for technological advancements for the Sonablate® 500 system and/or other ultrasound applications.

The Sonablate® 500 is approved for investigational use within the U.S. and is being studied for the treatment of prostate cancer in clinical trials in the U.S. The FDA has made no decision as to the safety or efficacy of the Sonablate® 500 for the treatment of prostate cancer. Currently, the device is available for the treatment of prostate cancer outside the U.S. in more than 30 countries.

US HIFU was founded in 2004 and is headquartered in Charlotte, N.C. Additional information may be found at www.ushifu.com.

About Galen Partners

Galen Partners (Galen) is a leading healthcare growth equity, late stage venture capital firm based in Stamford, Connecticut. The firm focuses on growth equity investments in healthcare technology-enabled services, medical devices and specialty pharmaceutical companies. With nearly $1 billion under management raised through five funds, Galen has invested in more than 70 companies since 1990. The firm continues a tradition of strategic collaboration and partnership with its portfolio company management teams to build healthcare market leaders. Please visit Galen's website at www.galen.com.

 

 


'/>"/>
SOURCE USHIFU, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
2. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
3. Xytis Names Gordon H. Busenbark as Chief Financial Officer
4. PLC Medical Systems Names Lead Investigators for Pivotal Trial to Evaluate RenalGuard System(TM) and RenalGuard Therapy(TM)
5. Association of Clinical Research Organizations (ACRO) Names Dr. Derek Winstanly Chair-Elect
6. California Cryobank Names Richard Jennings President of FamilyCord Division
7. Zeltiq Aesthetics Names Gordie Nye to Serve as New CEO
8. ParagonRx Names Ellen M. Derrico To Chief Marketing Executive Post
9. Boston Business Journal Names NxStage(R) Medical Third Fastest Growing Company in Massachusetts
10. NovaBay Pharmaceuticals Expands Management Team; Names Mark Anderson, Ph.D. as Chief Scientific Officer
11. ThermoGenesis Names Jorge Artiles Vice President, Chief Quality and Regulatory Affairs Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... Mass. , March 28, 2017 ... company developing innovative therapeutics that address significant unmet ... a patent from the Japan Patent Office (JPO) ... connective tissue growth factor (CTGF) for the treatment ... limited to skin fibrosis and proliferative retinopathy (Japanese ...
(Date:3/28/2017)... , March 28, 2017 ... research with Cambridge ... Consortium   The Milner Therapeutics Institute today announces ... Elysium Health has committed significant investment for collaborative projects with ... next four years. This is the first major research investment ...
(Date:3/27/2017)... TEL-AVIV, Israel , March 27, 2017 /PRNewswire/ ... TASE: THXBY), a specialty clinical-stage pharmaceutical company specializing in the ... of its public offering in the ... Shares (ADSs), each ADS representing 40 ordinary shares ... per ADS. In addition, Therapix has granted the ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... Z-Medica, ... University of Pittsburgh Medical Center (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) ... program, developed in association with efforts by the American College of Surgeons, U.S. ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... laboratory instruments are critical to ensuring high-quality results and maintaining GMP and USP ... of Laboratory Instruments in accordance with GMP requirements " these requirements are explained. ...
(Date:3/28/2017)... ... 28, 2017 , ... With less than 10,000 dermatologists in the United States ... be limited while the desire to conquer breakouts and eliminate skincare stress is widespread. ... customer online, today released its inaugural survey on the State of Acne in America. ...
(Date:3/28/2017)... ... , ... Columbus OH. Dr. Justin Harper, Founder of Juvly Aesthetics in Ohio ... country to sit on the 2017 National Advisory Board for Allergan’s Facial Aesthetics National ... helped propel the clinic from a small start-up to number 78 in the country ...
(Date:3/28/2017)... ... March 28, 2017 , ... Public relations pros work hard to ... of business channels. , While many results are clear, much of PR is hard ... , When it comes to measurement, firms should always take an all-inclusive approach that ...
Breaking Medicine News(10 mins):